European Union - English - EMA (European Medicines Agency)

glaxosmithkline trading services limited - albiglutide - diabetes mellitus, type 2 - drugs used in diabetes - eperzan is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control as:monotherapywhen diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to contraindications or intolerance.add-on combination therapyin combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 4.4 and 5.1 for available data on different combinations).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - albiglutide - powder and solvent for solution for injection - 30mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - albiglutide - powder and solvent for solution for injection - 50mg

Canada - English - Health Canada

glaxosmithkline inc - albiglutide - powder for solution - 30mg - albiglutide 30mg - miscellaneous antidiabetic agents

Canada - English - Health Canada

glaxosmithkline inc - albiglutide - powder for solution - 50mg - albiglutide 50mg - miscellaneous antidiabetic agents